Overview

Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of telbivudine 600mg versus adefovir dipivoxil 10mg in patients with compensated chronic hepatitis B.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Adefovir
Adefovir dipivoxil
Telbivudine